LAWRENCEVILLE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback